Goreisan attenuates cardiac hypertrophy and diastolic dysfunction in heart failure with preserved ejection fraction induced by HFD/L-NAME via regulation of ICAT-β-catenin/ERK axis
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-09-03 22:28
摘要：
Goreisan, a traditional herbal formulation, has shown promise in alleviating cardiac hypertrophy and diastolic dysfunction associated with heart failure with preserved ejection fraction (HFpEF). The study identifies its mechanism of action through the regulation of the ICAT-β-catenin/ERK signaling pathway. This research highlights the increasing global prevalence of HFpEF and positions Goreisan as a potential novel therapeutic option in cardiovascular treatment, warranting further clinical investigation.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
Goreisan attenuates cardiac hypertrophy and diastolic dysfunction in HFpEF.
Mechanistically, it suppresses the phosphorylation of MAPKs and regulates the ICAT-β-catenin/ERK axis.
The study indicates a potential therapeutic role for Goreisan in managing HFpEF.
真实性检查
否
AI评分总结
Goreisan, a traditional herbal formulation, has shown promise in alleviating cardiac hypertrophy and diastolic dysfunction associated with heart failure with preserved ejection fraction (HFpEF). The study identifies its mechanism of action through the regulation of the ICAT-β-catenin/ERK signaling pathway. This research highlights the increasing global prevalence of HFpEF and positions Goreisan as a potential novel therapeutic option in cardiovascular treatment, warranting further clinical investigation.